In vivo brain imaging of tangle burden in humans

Journal of Molecular Neuroscience

Volumn 19, Issue 3, 2002, Pages 321-327

  Small, Gary W ^a,b,c   Agdeppa, Eric D ^a   Kepe, Vladimir ^a   Satyamurthy, Nagichettiar ^a   Huang, Sung Cheng ^a   Barrio, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Cerebral glucose metabolism; Neurofibrillary tangles; Positron emission tomography

Indexed keywords

APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN REGION; GLUCOSE METABOLISM; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; LIPOPHILICITY; NERVE CELL MEMBRANE; NEUROFIBRILLARY TANGLE; POSITRON EMISSION TOMOGRAPHY; REVIEW; SENILE PLAQUE;

EID: 0036931756     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1385/jmn:19:3:321     Document Type: Review

References (27)

1. Ashburn T. T., Han H., McGuinness B. F., and Lansbury P. T. (1996) Amyloid probes based on Congo Red distinguish between fibrils comprising different peptides. Chem. Biol. 3, 351-358.
2. Barrio J. R., Huang S.-C., Cole G. M., Satyamurthy N., Petric A., and Small G. W. (1999) PET imaging of tangles and plaques in Alzheimer disease. J. Nucl. Med. 40(Suppl.), 70P-71P.
3. Braak E., Griffing K., Arai K., Bohl J., Bratzke H., and Braak H. (1999) Neuropathology of Alzheimer's disease: What is new since A. Alzheimer? Eur. Arch. Psychiatry Clin. Neurosci. 249(Suppl. 3), III/14-III/22.
4. Braak H. and Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neurapathol. 82, 239-259.
5. Cherry S. R., Shao Y., Silverman R. W., et al. (1997) MicroPET: A high resolution PET scanner for imaging small animals. IEEE Trans. Nucl. Sci. NS-44, 1161-1166.
6. Dickson D. W. (1997) Neuropathological diagnosis of Alzheimer's disease: A perspective from longitudinal clinicopahtological studies. Neurobiol. Aging 18, S21-S26.
7. Ghebremedhin E., Schultz C., Braak E., and Braak H. (1998) High frequency of apolipoprotein E ∑4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp. Neurol. 153, 152-155.
8. Gotz J., Tolnay M., Barmettler R., Ferrari A., Burki K., Goedert M., et al. (2001) Human tau transgenic mice, in Neuropathology and Genetics of Dementia (Tolnay M. and Probst A., eds.), Kluwer Academic/Plenum, New York.
9. Hoffman E. J., Huang S.-C., and Phelps M. E. (1979) Quantitation in positron emission computed tomography: 1. Effect of object size. J. Comp. Assist. Tomogr. 3, 299-308.
10. Huang S.-C., Barrio J. R., and Phelps M. E. (1986) Neuroreceptor assay with positron emission tomography: Equilibrium versus dynamic approaches. J. Cereb. Blood Flow Metab. 6, 515-521.
11. Jacobson A., Petric A., Hogenkamp D., Sinur A., and Barrio J. R. (1996) 1,1-Dicyano-2-(6-dimethylamino)naphthalen-2-yl)propene (DDNP): A solvent polarity and viscosity sensitive fluorophore for fluorescence microscopy. J. Am. Chem. Soc. 118, 5572-5579.
12. Kirschner D. A., Abraham C., and Selkoe D. J. (1986) X-ray diffraction from intraneuronal paired helical filaments and extraneuronal amyloid fibers in Alzheimer disease indicates cross-β conformation. Proc. Natl. Acad. Sci. USA 83, 503-507.
13. Klunk W. E., Debnath M. L., and Pettegrew J. W. (1995) Chrysamine-G binding to Alzheimer and control brain: Autopsy study of a new amyloid probe. Neurobiol. Aging 16, 541-548.
14. Lovat L. B., O'Brien A. A., Armstrong S. F., et al. (1998) Scintigraphy with 123I-serum amyloid P component in Alzheimer disease. Alzheimer's Dis. Assoc. Disord. 12, 208-210.
15. Majocha R. E., Reno J. M., Friedland R. P., VanHaight C., Lyle L. R., and Marotta C. A. (1992) Development of a monoclonal antibody specific for beta/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. J. Nucl. Med. 33, 2184-2189.
16. Motter R., Vigo-Pelfrey C., Kholodenko D., et al. (1995) Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38, 643-648.
17. Nagy Z., Esiri M. M., Jobst K. A., Morris J. H., King E. M.-F., McDonald B., et al. (1997) The effects of additional pathology on the cognitive deficit in Alzheimer disease. J. Neuropath. Exp. Neurol. 56, 165-170.
18. Phelps M. E., Huang S. C., Hoffman E. J., Selin C. E., and Kuhl D. E. (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxyglucose: Validation of method. Ann. Neurol. 6, 371-388.
19. Price J. L., Davis P. G., Morris J. C., and White D. L. (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol. Aging 12, 295-312.
20. Price J. L. and Morris J. C. (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358-368.
21. Reiman E. M., Caselli R. J., Yun L. S., et al. (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N. Engl. J. Med. 334, 752-758.
22. Reiman E. M., Caselli R. J., Chen K., Alexander G. E., Bandy D., and Frost J. (2001) Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98, 3334-3339.
23. Shoghi-Jadid K., Small G. W., Agdeppa E. D., Kepe V., Ercoli L.M., Siddarth P., et al. (2002) Localization of neurofibrillary tangles (NFTs) and beta-amyloid plaques (APs) in the brains of living patients with Alzheimer's disease. Am. J. Geriatr. Psychiatry 10, 24-35.
24. Small G. W., Mazziotta J. C., Collins M. T., Baxter L. R., Phelps M. E., Mandelkern M. A., et al. (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942-947.
25. Small G. W., Rabins P. V., Barry P. P., Buckholtz N. S., DeKosky S. T., Ferris S. H., et al. (1997) Diagnosis and treatment of Alzheimer disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 278, 1363-1371.
26. Small G. W., Ercoli L. M., Silverman D. H. S., Huang S.-C., Komo S., Bookheimer S. Y., et al. (2000) Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 97, 6037-6042.
27. Yang J., Huang S.-C., Mega M., Lin K. P., Toga A., Small G. W., et al. (1996) Investigation of partial volume correction methods for brain FDG-PET studies. IEEE Trans. Nucl. Sci. NS-43, 3322-3327.